Asset Details
Do you wish to reserve the book?
Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical Needs
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical Needs
Do you wish to request the book?
Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical Needs
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical Needs
2024
Overview
The US Food and Drug Administration recognizes the unmet medical need for antibacterial drugs to treat serious bacterial diseases caused by resistant pathogens for which effective therapies are limited or lacking. The agency also recognizes that designing and conducting clinical trials to assess the safety and efficacy of drugs to treat resistant infections is challenging, especially for drugs only active against a single or a few bacterial species, and that a more flexible development program might be appropriate. In this article, we discuss several regulatory considerations for flexible development programs for antibacterial drugs intended to meet an unmet medical need. As an example, we use the recent approval of sulbactam for injection and durlobactam for injection (XACDURO) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
Publisher
U.S. National Center for Infectious Diseases,Centers for Disease Control and Prevention
Subject
Acinetobacter baumannii - drug effects
/ Anti-Bacterial Agents - pharmacology
/ Anti-Bacterial Agents - therapeutic use
/ bacteria
/ carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex
/ Drugs
/ Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical Needs
/ Humans
/ Methods
Seems like something went wrong :( Kindly try again later!